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Background: Oncolytic viruses represent a promising therapy against cancers with acquired drug resistance.
However, low efficacy limits its clinical application. The objective of this study is to investigate whether
pharmacologically modulating autophagy could enhance oncolytic Newcastle disease virus (NDV) strain NDV/FMW
virotherapy of drug-resistant lung cancer cells.
Methods: The effect of NDV/FMW infection on autophagy machinery in A549 lung cancer cell lines resistant to
cisplatin (A549/DDP) or paclitaxel (A549/PTX) was investigated by detection of GFP-microtubule-associated protein 1
light chain 3 (GFP-LC3) puncta, formation of double-membrane vesicles and conversion of the nonlipidated form of
LC3 (LC3-I) to the phosphatidylethanolamine-conjugated form (LC3-II). The effects of autophagy inhibitor chloroquine
(CQ) and autophagy inducer rapamycin on NDV/FMW-mediated antitumor activity were evaluated both in culture cells
and in mice bearing drug-resistant lung cancer cells.
Results: We show that NDV/FMW triggers autophagy in A549/PTX cells via dampening the class I PI3K/Akt/mTOR/
p70S6K pathway, which inhibits autophagy. On the contrary, NDV/FMW infection attenuates the autophagic process in
A549/DDP cells through the activation of the negative regulatory pathway. Furthermore, combination with CQ or
knockdown of ATG5 significantly enhances NDV/FMW-mediated antitumor effects on A549/DDP cells, while the
oncolytic efficacy of NDV/FMW in A549/PTX cells is significantly improved by rapamycin. Interestingly, autophagy
modulation does not increase virus progeny in these drug resistant cells. Importantly, CQ or rapamycin significantly
potentiates NDV/FMW oncolytic activity in mice bearing A549/DDP or A549/PTX cells respectively.
Conclusions: These results demonstrate that combination treatment with autophagy modulators is an effective
strategy to augment the therapeutic activity of NDV/FMW against drug-resistant lung cancers.
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Acquired drug resistance to first-line chemotherapeutics,
such as cisplatin and paclitaxel, is a major factor contrib-
uting to chemotherapy failure in non-small cell lung
cancer (NSCLC) patients [1,2]. Oncolytic viruses (OVs)
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unless otherwise stated.great potential for the treatment of drug-resistant lung
cancers [3]. We previously reported that the oncolytic
Newcastle disease virus (NDV) induces apoptosis in
cisplatin-resistant A549 (A549/DDP) cells in vitro and
in vivo [4]. NDV is an avian paramyxovirus that selectively
replicates in a variety of tumor cells but not in normal hu-
man cells [5]. NDV strains such as LaSota, Ulster [6], 73-T
[7], NDV/FMW [8,9], and NDV- HUJ [10,11] have dis-
played oncolytic effects in lung cancer cells. Notably, in
addition to triggering apoptosis in chemo-resistant malig-
nant primary melanoma [12], oncolytic NDV induces effi-
cient oncolysis in human lung adenocarcinoma A549 cellstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[13]. These studies and studies from our lab indicate a
potential role of oncolytic NDV in the treatment of drug-
resistant lung cancers. However, it remains a challenge to
improve the efficacy of NDV in drug-resistant NSCLC
cells in preclinical and clinical tests.
Oncolytic NDV is known to trigger apoptosis pathways
in infected tumor cells [4,8,10,14-16]. In addition to
targeting the cellular apoptosis machinery, we recently
reported that oncolytic NDV induces autophagy in U251
human glioma cells to promote virus production [17],
suggesting that autophagy may be involved in NDV-
induced oncolysis. Autophagy is a conserved homeostatic
mechanism of lysosomal degradation [18]. The hallmark
of autophagy is a double-membraned autophagosome that
engulfs long-lived cytoplasmic macromolecules and dam-
aged organelles [19]. Autophagy is mainly modulated by
the mTOR (mammalian target of rapamycin) and PI3K
(phosphatidylinositol 3-kinase) pathways, which are class I
(inhibitory to autophagy) and class III (necessary for the
execution of autophagy) modulators [20,21]. Accumulat-
ing evidence reveals that OVs interact with the autophagy
machinery in infected tumor cells, and autophagy plays a
role in OV-mediated cancer cell death [22-24]. Of note, a
number of studies reported that the pharmacological
modulation of autophagy augments the anti-tumor effects
of OVs, such as the oncolytic adenovirus OBP-405 in
combination with the autophagy inducers temozolomide,
rapamycin and RAD001 in glioma cells [25], dl922-947 in
combination with the autophagy inhibitor chloroquine
(CQ) in glioma cells [26], Ad-cycE with rapamycin in lung
cancer cells [27]. In addition, autophagy plays critical roles
in both innate and adaptive immuninity. It has been shown
that autophagy enhances tumor immunogenicity via releas-
ing damage-associated molecular pattern (DAMP) mole-
cules by dying cells with autophagy and promoting antigen
cross presentation from cancer cells by DCs to naive T cells
[28,29]. Since OV infections can interact with the cellular
autophagy machinery, OV in combination with an autoph-
agy modulator would enhance the antitumor immune re-
sponses, thereby improving OV-mediated efficacy [29-31].
Together, data from these studies strongly indicate that
targeting autophagy may be utilized as a novel strategy for
enhancing the oncolytic virotherapy of cancers.
The objective of this study was to investigate whether
pharmacologically targeting autophagy could enhance
NDV virotherapy in drug-resistant lung cancer cells. We
first dissected the interaction between NDV and the
cellular autophagy machinery in cisplatin- and paclitaxel-
resistant A549 lung cancer cells and further demonstrated
that the modulation of autophagy with rapamycin or CQ
enhances the NDV-mediated anti-tumor effects on drug-
resistant A549 cells in vitro and in vivo. Therefore, our re-
sults suggest that combination with chemotherapeuticagents that modulate autophagy may be a potential strat-
egy to optimize the clinical efficacy of oncolytic NDV.
Methods
Cell lines, mice and virus preparation
A549 human lung cancer cell line and chicken embryo
fibroblast cell line DF1 was purchased from American
Type Culture Collection (ATCC) and cultured at 37°C
and 5% CO2 in DMEM supplemented with 10% fetal bo-
vine serum (FBS). Cisplatin-resistant A549 (A549/DDP)
cells [4] were cultured in DMEM containing 2 μg/mL cis-
platin (Sigma) to maintain resistance. An A549-derived
paclitaxel-resistant sub-line, A549/PTX, was kindly pro-
vided by Dr. Sang Kook Lee (Seoul National University)
and cultured in RPMI 1640 containing 100 ng/mL pacli-
taxel (Sigma) to maintain resistance [32]. The cells were
cultured in complete media without cisplatin or paclitaxel
for 3 days before performing experiments. The NDV
strain NDV/FMW, which has been previously shown to
be oncolytic in A549/DDP and parental cells [4,8], was
used throughout the study. Virus passaging, propagation,
and titration were performed as previously described, and
virus titer was expressed as log10 50% tissue culture infect-
ive dose (TCID50) [8]. BALB/c nude mice (female, 4–6
weeks old) were purchased from the Experimental Animal
Center of Dalian Medical University (Dalian, China) and
all procedures involving animals and their care complied
with the China National Institutes of Healthy Guidelines
for the Care and Use of Laboratory Animals. Ethical ap-
proval for the study was granted by the Ethics Committee
of Dalian Medical University.
Antibodies and reagents
The monoclonal anti-Beclin-1 antibody and high-mobility
group box1(HMGB1) were purchased from Santa Cruz.
The polyclonal rabbit anti-microtubule-associated protein
1A/1B-light chain 3 (LC3) and a monoclonal antibody
against β-Actin were obtained from Sigma. The following
antibodies were purchased from Cell Signaling Technol-
ogy: cleaved caspase-3 and phospho-specific antibodies to
mTOR (Ser2448), Akt (Ser473) and p70 ribosomal protein
S6 kinase (S6K) (Thr389), along with total antibodies di-
rected against mTOR, Akt, and p70S6K. Rapamycin and
chloroquine (CQ) were purchased from Sigma.
Virus infection
A549/DDP, A549/PTX, and parental A549 cells were
infected with NDV/FMW at a multiplicity of infection
(MOI) of 10, or they were sham-infected with phosphate-
buffered saline (PBS), at 37°C for 1 h in serum-free
DMEM. The cells were washed three times with PBS and
incubated at 37°C in reduced serum (1% FBS)-containing
media. For the pharmacological modulation of autophagy,
cells were treated with rapamycin (100 nM) or CQ (5 μM)
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were infected with NDV/FMW in the presence or absence
of various compounds for 1 h and then cultured in fresh
DMEM or RPMI 1640 containing rapamycin or CQ for
the indicated times. For experiments that involved the
determination of virus yield, tumor cells were infected
with NDV/FMW at an MOI of 0.01, and multi-step viral
growth curves were measured as previously described [8].
Cell transfection and fluorescence microscopy
Tumor cells were transfected with a plasmid expressing
green fluorescent protein (GFP)-LC3 using Lipofectamine
2000 according to the manufacturer’s instructions. Dot
formation by GFP-LC3 was detected with a fluorescence
microscope (BX50, Olympus) following drug treatment
and/or NDV/FMW infection. Transfected cells with five
or more puncta were considered to have accumulated
autophagosomes. A total of 100 transfected cells were ex-
amined per well in triplicate from three independent
experiments.
RNA interference
RNA interference was used to knock down ATG5, a key
gene for autophage formation. Two siRNA oligonucleo-
tides were used: ① 5'-TGA TAT AGC GTG AAA CAA
G-3' [33]; ② 5'-CAA CTT GTT TCA CGC TAT A–3'
[34]. Transfection of siRNA was performed as described
previously [17,35]. A scrambled siRNA was used as a
negative control. The silencing efficiency was detected by
immunoblot. At 48 h after transfection, cells were infected
with NDV/FMW at an MOI of 10 for various times.
Transmission electron microscopy analysis
Standard transmission electron microscopy (TEM) was
performed as previously described [17]. Briefly, 24 h after
NDV/FMW infection, the cells were fixed and embedded.
Thin sections (90 nm) were examined at 80 kV with a JEOL
1200EX transmission electron microscope. Approximately
15 cells were counted, and autophagosomes were defined
as double-membrane vacuoles measuring 0.5 or 2.0 μm.
Cell proliferation assay
Tumor cells were seeded into 96-well plates, and cell
growth was measured daily by the MTTassay as previously
described [8]. The experiments were repeated three times.
Flow cytometric analysis of apoptosis
Apoptosis was quantified using flow cytometry as previ-
ously described [8]. Briefly, tumor cells were seeded at
1 × 105 cells/dish in 60-mm dishes and treated with
NDV/FMW at an MOI of 10. Floating cells and cell
pellets were prepared for the annexin V-fluorescein iso-
thiocyanate (FITC) and propidium iodide (PI) double-
staining procedure. The cell population in the lowerright quadrant (PI-negative, annexin V-positive) corre-
sponds to apoptotic cells. The data was determined in
three independent experiments.
Immunoblot assay
Immunoblot (IB) assays were performed as described
previously [36]. Densitometry analysis of the specific
protein expression was performed using a calibrated
GS-670 densitometer. All IB experiments were per-
formed in duplicate.
Animal experiments
Nude mice were subcutaneously inoculated in the flank with
A549/DDP and A549/PTX cells (5 × 106 cells in 100 μL
PBS/mouse) to induce tumor development. When tumors
reached an average volume of 200 mm3, tumor-bearing
mice were intratumorally inoculated with NDV/FMW. Mice
were randomly divided into four groups (six mice per
group): (a) vehicle treatment, (b) intraperitoneal (i.p.) treat-
ment with rapamycin (5 mg/kg) or CQ (45 mg/kg) alone
three times a week, (c) intratumoral administration with
NDV/FMW (1 × 107 TCID50 per dose) three times a week,
and (d) NDV/FMW treatment in combination with CQ or
rapamycin (same dose as described previously) administered
1 d prior to virus injection. One week after treatment, two
mice (of six) were sacrificed, and tumor sections (5 μm)
were subjected to either hematoxylin–eosin (H&E) staining
or terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay as previously described [4,9].
TUNEL-positive (brown staining) cells were characterized
as apoptotic cells, and 10 randomly selected microscopic
fields in each group were examined to calculate the ratio of
TUNEL-positive cells. Tumor tissue samples from two dif-
ferent mice (of six) from each treatment group were sub-
jected to immunoblot analysis to evaluate cleaved caspase-3
levels or LC3II abundance. Excised tumors from the other
two animals (of six) were subjected to virus isolation.
For the in vivo oncolysis study, 10 mice were included
in each treatment group, and the four mouse groups
were treated as described above for two weeks. At five-
day intervals, mice were examined for tumor growth or
survival. Tumor diameter was measured with a caliper,
and tumor volume was calculated based on the follow-
ing formula: volume = (greatest diameter) × (smallest
diameter)2/2. The experiment was terminated when
tumors reached 1 cm3 in volume and/or symptomatic
tumor ulceration occurred, and the surviving mice were
sacrificed under anesthesia.
Statistical analysis
Comparisons of data for all groups in the viral propaga-
tion and cytotoxicity assays were first performed using
one-way analysis of variance (ANOVA). Multiple compar-
isons between treatment groups and controls were
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(LSD) test. To assess in vivo oncolytic effects, statistical
significance between groups was calculated using the LSD
test in SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).
A p < 0.05 was considered statistically significant.
Results
NDV/FMW induces autophagosome formation in pacli-
taxel-resistant A549 cells but attenuates the autophagic
process in cisplatin-resistant A549 cells.
We previously reported that oncolytic NDV induces
apoptosis in cisplatin-resistant A549 (A549/DDP) and
parental cells [4,8]. Here, we show that marked caspase-
3 cleavage was detected in paclitaxel-resistant A549
(A549/PTX) cells upon NDV/FMW infection (Figure 1,
left panel), indicating that NDV/FMW infection induces
apoptosis in paclitaxel-resistant A549 cells. Our recent
study revealed that NDV infection activated autophagy
in cancer cells [17]; however, the significance related to
NDV-mediated oncolysis has not been elucidated. To in-
vestigate whether NDV/FMW interacts with the autoph-
agy machinery in drug-resistant A549 and parental cells,
we first examined the conversion of LC3I (cytosolic
form) to LC3II (autophagosome-bound lipidated form),
a hallmark of autophagy [37]. Consistent with a previous
report [38], A549/DDP cells displayed high basal levels
of LC3II, which remained unchanged upon NDV/FMW
infection at 4 and 8 hours post-infection (hpi) (Figure 1A,
middle panel). However, the LC3II abundance was mark-
edly diminished at 12 and 24 hpi (Figure 1A, middle
panel), suggesting that NDV infection reduces LC3 con-
version in the late stage of viral infection. In contrast, in-
creased LC3II abundance was detected in A549/PTX
and parental cells after NDV/FMW infection (Figure 1A,
left and right panels), indicating that NDV infection in-
duces LC3 conversion in these cells.
To determine whether NDV/FMW perturbs autophago-
some formation in drug-resistant A549 cells, we detected
GFP-LC3 dot formation, which is generally regarded as an
autophagosome [37]. A549/DDP, A549/PTX, and parental
cells were transfected with GFP-LC3 and then mock-
infected or infected with NDV/FMW at an MOI of 10. As
shown in Figures 1B and D, the GFP-LC3 redistribution
into discrete dots was significantly increased in NDV/
FMW -infected A549/PTX (**p < 0.01) and parental
(**p < 0.01) cells at 24 hpi, while a diffuse cytoplasmic dis-
tribution of fluorescence was observed in mock-treated
A549/PTX and parental cells. Interestingly, marked punc-
tated GFP-LC3 accumulation was observed in mock-
infected A549/DDP cells (Figure 1C), suggesting a high
basal level of autophagy. However, upon NDV/FMW in-
fection, the number of A549/DDP cells with punctated
GFP-LC3 was significantly diminished compared to basal
levels (Figure 1C, **p < 0.01). Control cells treated withthe autophagy inducer rapamycin exhibited typical GFP-
LC3 dot formation. In addition, TEM-based ultrastructural
analysis of the formation of double-membrane vesicles
(autophagosomes) confirmed the above findings (Figures 1E,
F, and G). Therefore, these results indicate that NDV/FMW
induces autophagosome formation in A549/PTX and par-
ental cells, whereas it inhibits the autophagic process in
A549/DDP cells.
NDV/FMW infection perturbs autophagic signaling
pathways in drug-resistant A549 cells
To elucidate the underlying mechanisms of the different
patterns of autophagy modulation in various drug-
resistant A549 cells upon NDV/FMW infection, we
examined the class I PI3K/Akt/mTOR/p70S6K and
class III PI3K/Beclin-1 pathways, which negatively (the
former) or positively (the latter) regulate autophagosome
formation [20,21]. As shown in Figure 2A (left and right
panels), NDV/FMW infection reduced the phosphoryl-
ation levels of Akt in A549/PTX and A549 cells in a
time-dependent manner, indicating inhibition of the
negative regulatory pathway in autophagy. In line with
our previous work [4], we observed a time-dependent
increase in Akt phosphorylation in A549/DDP cells
upon NDV/FMW infection (Figure 2A, middle panel),
indicating activation of the negative regulatory pathway
in autophagy. Accordingly, we detected increased mTOR
and p70S6K phosphorylation in NDV/FMW -infected
A549/DDP cells (Figure 2A, middle panel) and marked
reductions in mTOR and p70S6K phosphorylation in
A549/PTX and parental cells (Figure 2A, left and right
panels). No change was detected in the levels of total
Akt, mTOR, and p70S6K. Together, these observations
indicate that the class I PI3K/Akt/mTOR/p70S6K signal-
ing pathway contribute to the interaction between the
NDV and autophagy machinery in drug-resistant A549
and parental cells.
Beclin-1 forms a complex with class III PI3K and plays
an essential role in controlling the first steps of autoph-
agy commitment [39]. We found that beclin-1 expres-
sion was up-regulated in a time-dependent manner in
NDV-infected A549/PTX and parental cells (Figure 2B,
left and right panels), suggesting that beclin-1 may par-
ticipate in the induction of autophagosome formation in
these cells during NDV/FMW infection. Upon NDV/
FMW infection, the expression of beclin-1 in A549/DDP
cells was nearly unchanged from 4 to 12 hpi and was
completely diminished at 24 hpi (Figure 2B, middle
panel), suggesting that NDV/FMW infection decreases
beclin-1 expression in the late stage of infection. There-
fore, these data indicate that the class III PI3K/Beclin-1
pathway may be involved in the interplay between NDV/
FMW and the cellular autophagy machinery in drug-
resistant A549 and parental cells.
Figure 1 (See legend on next page.)
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Figure 1 Oncolytic NDV/FMW induces apoptosis and modulates autophagy in drug-resistant lung cancer cells. Paclitaxel-resistant A549
(A549/PTX) and cisplatin-resistant A549 (A549/DDP) and parental cells were infected with NDV/FMW at a multiplicity of infection (MOI) of 10, and at
the indicated time points. (A) Activation of caspase-3 and LC3I to LC3II conversion were analyzed by immunoblot (IB) assay, using β-Actin as a loading
control. R stands for rapamycin, an autophagy inducer used as the positive control. Densitometry was performed for quantification, and the ratios of
LC3II to β-Actin are presented below the blots. The results shown are representative of two separate experiments. (B-D) Drug-reisistant A549 and
parental cells were transfected with GFP-LC3, followed by NDV/FMW infection for 24 h. The pictures show mock-infected cells, cells treated with
rapamycin for 24 h as a positive control. The number of cells with punctated GFP-LC3 is displayed as a histogram. *p < 0.05;**p < 0.01. (E-G)
Transmission electron microscopy analysis of cells infected with NDV/FMW for 24 h. (E) NDV/FMW-infected A549/PTX cells displayed more vacuolated
(indicated by the arrows) than control (uninfected cells), the enlarged image showed initial autophagosomes (AVi) and a swollen mitochondrion (M) in
infected A549/PTX cells. (F) Uninfected-A549/DDP cells showed disappearance of most organelles, the two limiting membranes of the autophagosome
are visible in enlarged image (indicated by the arrows), and infected A549/DDP cells showed normal distribution of organelles and few autophagic
structures. (G) Infected A549 cells showed highly autophagosome (indicated by the arrows) rather than uninfected A549 cells, clearer autophagosome
showed in the enlarged image. Data shown are representative of three independent experiments.
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NDV/FMW-induced cytotoxicity
We sought to elucidate whether the efficacy of the oncoly-
tic NDV/FMW virotherapy of drug-resistant lung cancer
cells could be enhanced by combination with autophagy
modulators. To this end, we used the autophagy inducer
rapamycin and the autophagy inhibitor CQ because these
two compounds and their analogs, including RAD001 and
hydroxychloroquine, have been widely employed to po-
tentiate the anti-tumor effects of several oncolytic viruses
in preclinical settings. Importantly, these compounds have
been approved for use in clinical trials [25,40-42]. Rapa-
mycin selectively targets mTOR to stimulate autophagy,
while CQ is known to disrupt autophagosome-lysosome
fusion, leading to the accumulation of autophagic vacu-
oles, as demonstrated by a marked accumulation of LC3II
[43,44]. Importantly, CQ has been used to overcome re-
sistance of lung carcinoma cells to different chemothera-
putics such as the dual PI3K/mTOR inhibitor PI103 and
crizotinib [45,46], while rapamycin has been administrated
in a phase I trial of patients with advanced non-small cell
lung cancer [47]. The two compounds had no effect on
cell viability at the concentrations used in our preliminary
trial. As seen in Figure 3A, the pre-addition of either rapa-
mycin or CQ to drug-resistant A549 and parental cells re-
sulted in enhanced LC3II accumulation upon NDV/FMW
infection compared with control infection. Together, these
results indicate an enhanced induction of autophagy by
rapamycin and inhibition of autophagosome-lysosome fu-
sion by CQ in infected cells.
We then examined whether the pharmacological
modulation of autophagy had an effect on NDV/FMW-
mediated cytotoxicity. NDV/FMW-mediated cell death
in rapamycin-treated A549/PTX and CQ-treated A549/
DDP cells was significantly augmented as determined by
the MTT assay (Figure 3B). FACS analysis demonstrated
that the pre-addition of rapamycin rather than CQ to
A549/PTX cells significantly increased the number of
apoptotic cells upon NDV/FMW infection compared
with NDV/FMW infection alone (Figure 3C and 3D,*p < 0.05; **p < 0.01), supporting by the observation that
treatment with rapamycin but not CQ enhanced the
cleavage of caspase 3 in NDV/FMW-infected A549/
PTX cells compared with virus alone (Figure 3A).
Together, these results suggest that autophagy may
function as a death mechanism in NDV/FMW-infected
A549/PTX cells, and augmenting the autophagic re-
sponse with rapamycin increases viral cytotoxicity. Con-
versely, CQ, but not rapamycin, increased the activation
of caspase-3 in NDV/FMW-infected A549/DDP cells
compared with NDV/FMW infection alone (Figure 3A),
while treatment with CQ rather than rapamycin signifi-
cantly increased apoptosis and necrosis or a late necro-
sis consecutive to apoptosis in NDV/FMW-infected
A549/DDP cells, as demonstrated by the FACS analysis
(Figure 3C and 3D, **p <0.01). These data indicate that
autophagy may act as a survival mechanism in NDV/
FMW-infected A549/DDP cells, and the attenuation of
the autophagic response enhances viral oncolysis. Inter-
estingly, treatment with neither rapamycin nor CQ
exerted an effect on the cleavage of caspase-3 in NDV/
FMW-infected A549 cells (Figure 3A). As expected, no
significant change in the number of apoptotic cells was
detected in rapamycin- or CQ-treated A549 cells upon
NDV/FMW infection (Figure 3C and 3D). Together, these
data suggest that autophagy may not contribute to cell
death or survival in NDV/FMW-infected A549 cells.
Knockdown of autophagy-related gene ATG5 augments
NDV/FMW-mediated oncolysis in cisplatin-resistant A549
cells
The data shown above indicated that pharmacological
modulation of autophagy enhances NDV/FMW-in-
duced cytotoxicity. However, both rapamycin and CQ
can sensitize cells towards cell death via multiple mech-
anisms that depend or not on autophagy. For instance,
CQ can lead to apoptosis or necrosis by inducing lyso-
somal permeabilization [45]. To further ascertain the
role of autophagy in NDV/FMW-mediated oncolysis in
drug-resistant A549 cells, we knocked down expression
Figure 2 Autophagic signaling pathways are regulated in response to NDV/FMW infection in drug-resistant lung cancer cells. A549/
DDP and A549/PTX as well as parental cells were infected with NDV/FMW at an MOI of 10 at the indicated time points. Expression of beclin-1
(B), total and phosphorylated (p-) Akt, mTOR and p70S6K (A) was analyzed by immunoblot, using β-Actin as a loading control. R stands for
rapamycin, an autophagy inducer inhibiting mTOR phosphorylation. The ratios of phosphorylated protein to β-Actin are presented below the
blots. Results shown are representative of three independent experiments.
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tion, in drug-resistant A549 and parent cells by using
specific siRNA targeting ATG5, and analyzed NDV/
FMW-induced cell death by MTT assay. As shown in
Figure 4A, cells transfected with small interfering RNAs
(siRNAs) specific to ATG5 exhibited an obvious de-
crease of endogenous ATG5 protein. Furthermore,
ATG5 knockdown significantly enhanced NDV/FMW-
induced cell death in A549/DDP cells (**p < 0.01) while
virus-induced cell death in A549/PTX and parent cells
was not affected by ATG5 knockdown, in line with data
in Figure 3B.
The execution of cell death requires an orchestrated
interplay between three important processes: apoptosis,
necrosis and autophagy [48,49]. Data in Figure 3C indi-
cated that dying cells that are double positive for PI and
annexin were detected in A549/DDP cells treated with
NVD/FMW or NVD/FMW with CQ at 48 hpi, suggestingthat some of the cells might die via necrosis or a late ne-
crosis consecutive to apoptosis upon virus infection and
the combination treatment. To explore whether NDV-
induced necrosis was modulated by regulation of autoph-
agy, we knocked down the ATG5 protein expression using
specific siRNA targeting ATG5 in A549/DDP cells. As
shown in Figure 4D, at 48 hpi, markedly more dying cells
that are double positive for PI and annexin were observed
in ATG5-deficient A549/DDP cells than in A549/DDP
cells transfected with control siRNA, suggesting that
modulation of autophagy may exert an effect on NDV/
FMW-induced apoptosis and necrosis. Consistent with
the FACS data, we observed enhanced releasing of
HMGB1 protein, a known marker of immunogenic cell
death at late stages [28], in ATG5-deficient A549/DDP
cells at 48 hpi compared to A549/DDP cells transfected
with control siRNA (Figure 4C). We did not observe
marked increase in dying cells that are double positive for
Figure 3 (See legend on next page.)
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Figure 3 Pharmacological autophagy modulators enhance NDV/FMW-induced cytotoxicity. A549/DDP and A549/PTX as well as parental
cells were treated with chloroquine (CQ, or rapamycin or vehicle for 30 min and infected with NDV/FMW (MOI = 10) or mock-infected for various
times. (A) LC3II conversion and caspase-3 cleavage at 24 h post-infection were monitored by immunoblot analysis. The ratios of LC3II to β-Actin
are presented below the blots. CQ (7.5 μM) and rapamycin (125 nM) were used. (B) Cell viability at 24 and 48 h post-infection (hpi) was
determined by the MTT assay. CQ (5 μM) and rapamycin (100 nM) were used. Data presented are mean ± SD calculated from three independent
experiments (*p < 0.05; **p < 0.01). (C and D) Cells at 24 and 48 h post-infection were double-stained with annexin V-FITC and propidium iodide
(PI), apoptosis was assessed by FACS analysis. CQ (5 μM) and rapamycin (100 nM) were used. Bar graph summarized the percentage of apoptotic
cells from three independent experiments (*p < 0.05, **p < 0.01).
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deficient A549/PTX cells upon NDV infection (data not
shown). Collectively, these results suggested that ATG5
knockdown enhanced NDV/FMW-mediated oncolysis in
A549/DDP cells.
Autophagy modulation does not increase virus progeny
in drug resistant cells
To examine whether the increased oncolysis in the pres-
ence of autophagy modulators is due to the activation of
apoptosis or increased viral propagation, we determined
virus yield in drug-resistant A549 and parental cells
treated with rapamycin or CQ. We did not observe any
significant alteration in virus yield in CQ- or rapamycin-
treated A549/PTX cells at the time points examined
compared with control infection (Figure 5A). Interest-
ingly, CQ treatment significantly reduced the yield of
NDV/FMW progeny in A549/DDP cells at 24, 48, and
72 hpi compared with mock-treated cells (**p <0.01),
while treatment with rapamycin did not alter the virus
titers (Figure 5B). However, rapamycin treatment signifi-
cantly increased virus yield in A549 cells, while CQ
treatment resulted in a significant reduction in virus
yield (Figure 5C, *p < 0.05; **p < 0.01), which is similar to
our previous observations in NDV-infected U251 cells
[17]. Therefore, these data suggest that the increase in
viral cytotoxicity in the presence of autophagy modula-
tors might not be due to altered viral propagation in
drug resistant A549 cells.
CQ or rapamycin potentiates NDV/FMW oncolytic activity
in mice bearing drug-resistant lung cancer cells
To validate the potential therapeutic use of autophagy
modulators in combination with NDV/FMW, we investi-
gated the oncolytic effects of the virus in combination
with CQ or rapamycin in mice bearing A549/DDP or
A549/PTX cells. The design of the in vivo experiments
was based on previous studies from our lab and others
[4,9,25,26,50,51]. Tumor-bearing mice were intraperito-
neally (i.p.) treated with vehicle, rapamycin, or CQ and
were intratumorally (i.t.) administered NDV/FMW after
24 hours. To study apoptosis, tumor sections were sub-
jected to either H&E staining or TUNEL assay. The
H&E-stained tumor sections from mice treated withNDV/FMW alone or NDV/FMW in combination with
CQ or rapamycin showed significant necrosis, including a
loss in nuclei and cell-cell adhesion, darkly stained and
condensed chromatin (Figures 6A and B upper, indicated
by the arrows); in contrast, there was less tumor necrosis
in tumor sections from mice treated with vehicle, CQ, or
rapamycin alone (Figures 6A and B upper). TUNEL stain-
ing of tissue sections from mice bearing A549/PTX cells
demonstrated that NDV/FMW in combination with rapa-
mycin induced more apoptotic cells than NDV/FMW,
rapamycin, or vehicle alone (Figure 6A lower), indicating
that rapamycin enhanced the in vivo oncolytic efficacy of
NDV/FMW in A549/PTX-derived tumor cells. Similarly,
in tumor sections from mice bearing A549/DDP cells,
increased numbers of apoptotic cells were observed in
mice treated with NDV/FMW in combination with CQ
than in mice treated with NDV/FMW, CQ, or vehicle
alone (Figure 6B lower). Further analyses of caspase-3 ac-
tivation in A549/PTX-derived tumors revealed that pre-
treatment with rapamycin led to more intense caspase-3
activation compared with the tumors that underwent
NDV/FMW treatment alone (Figure 6C). Similar results
were obtained for CQ-treated A549/DDP-derived tumors
infected with NDV/FMW (Figure 6D). The cleaved
caspase-3 levels were barely detectable in vehicle-, CQ-, or
rapamycin-treated tumors. Moreover, we observed that
NDV/FMW alone increased the LC3II/β-Actin ratio in
A549/PTX-derived tumors compared with vehicle-treated
tumors (Figure 6C), whereas it decreased the LC3II
abundance in A549/DDP-derived tumors compared with
the high basal level of LC3II in vehicle-treated tumors
(Figure 6D). Interestingly, treatment with CQ or rapamy-
cin alone was able to increase the LC3II/β-Actin ratio
in these tumors, and combination treatment further
strengthened this effect (Figures 6C and D).
We further investigated whether the in vivo combination
treatments resulted in enhanced inhibition of tumor cell
growth as demonstrated in our in vitro experiments. The
treatment of tumors bearing A549/PTX cells with rapamy-
cin alone or the addition of CQ to mice bearing A549/
DDP-derived tumors had negligible therapeutic effects on
tumor growth (Figures 6E and F). As expected, NDV/
FMW virotherapy markedly reduced tumor growth com-
pared with vehicle treatment (Figures 6E and F, p < 0.05,
Figure 4 (See legend on next page.)
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Figure 4 Knockdown of ATG5 enhances NDV/FMW-mediated oncolysis in A549/DDP cells. A549/DDP and A549/PTX as well as parental
cells were transfected with either specific siRNA targeting ATG5 or scrambled siRNA. (A) At 72 h after transfection, the levels of ATG5 and β-Actin
expression were measured by immunoblot analysis. (B) At 48 h after transfection, cells were infected with NDV/FMW (MOI =10) for 24 and 48 h
respectively. Cell death was determined by MTT assay. Bar graph summarized the percentage of cell death from three independent experiments
(*p < 0.05, **p < 0.01). (C, D) A549/DDP cells were transfected with either ATG5 siRNA or scrambled siRNA for 48 h, cells were then infected with
NDV/FMW (MOI =10) or mock-infected for indicated times. (C) Cell lysates at 24 hpi was analysed by immunoblot for ATG5, cleaved caspase-3
and β-Actin, while cell-free supernatant was collected and determined by immunoblot for high-mobility group box1(HMGB1) (D). At 24 and 48
hpi, cells were double-stained with annexin V-FITC and propidium iodide (PI), apoptosis was assessed by FACS analysis. Data shown are
representative of three independent experiments.
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with rapamycin induced a significant reduction in tumor
volume 5 days earlier than virus alone (Figure 6E, *p < 0.05;
**p < 0.01), and combination therapy also resulted in sig-
nificant tumor growth inhibition compared with virusFigure 5 Combination treatments do not enhance viral
propagation in drug-resistant lung cancer cells. A549/DDP and
A549/PTX as well as parental cells were treated with chloroquine (CQ,
5 μM) or rapamycin (100 nM) or vehicle for 30 min. (A-C) Cells were
then infected with NDV/FMW (MOI =0.01) for 24, 48 and 72 h
respectively. Virus yield was determined at different intervals. Data are
presented as the mean ± SD for triplicate assays (*p < 0.05, **p < 0.01).alone (Figure 6E). Similar effects were detected in mice
bearing A549/DDP cells treated with NDV in combin-
ation with CQ (Figure 6F). The difference in tumor vol-
ume assessed at each time point became statistically
significant at day 35 (all p values were lower than 0.05)
and day 45 (all p values were lower than 0.01). Together,
these data indicate that CQ and rapamycin are effective
in increasing the antitumor activity of NDV/FMW in
cisplatin- and paclitaxel-resistant A549 lung cancer cell
mouse models.
Discussion
Currently, the major limitation in the development of OVs
in clinical trials is the low efficacy of the viruses in vivo.
Here, we provide in vitro and in vivo evidence that pre-
treatment with the autophagy inhibitor CQ enhances
NDV/FMW-mediated antitumor effects in A549/DDP
cells via the inhibition of autophagy, while the autophagy
inducer rapamycin improves the oncolytic efficacy of
NDV/FMW in A549/PTX cells through enhanced autoph-
agy, suggesting that the combined administration of
autophagy modulators with oncolytic NDV/FMW may
improve virotherapy in lung cancer cells resistant to vari-
ous chemotherapies.
It is well known that viral infection and the cellular au-
tophagy machinery have complex interconnections. We
previously observed that NDV induces autophagy in U251
glioma cells [17]. In the current study, we showed that
oncolytic NDV/FMW triggers autophagy in A549/PTX
cells via the inhibition of the class I PI3K/Akt/mTOR/
p70S6K pathway, which negatively regulates autophagy.
However, NDV/FMW infection blocks the autophagic
process in A549/DDP cells through the activation of the
negative regulatory pathway. A plausible explanation for
the diverse strategies that regulate the cellular autophagy
machinery utilized by NDV/FMW is that the induction or
inhibition of autophagy by NDV/FMW may depend on
the role of autophagy in these drug-resistant lung cancer
cells. Autophagy may act as a survival or cell death mech-
anism in drug-resistant cancers. A previous study reported
that cisplatin treatment induces autophagy in A549 cells,
and the acquired cisplatin resistance in A549 cells is
associated with enhanced autophagy [38]. Another study
suggested that cisplatin-induced autophagy might provide a
Figure 6 (See legend on next page.)
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Figure 6 In vivo antitumor effects of NDV/FMW enhanced by chloroquine and rapamycin. Mice bearing A549/PTX or A549/DDP tumors
were randomized into four groups: (A) vehicle-treated, (B) rapamycin (5 mg/kg) via intraperitonealy (i. p.) three times a week, or chloroquine (CQ)
(45 mg/kg) alone via i.p. three times a week, (C) NDV/FMW (1 × 107 TCID50 per dose) via intratumoral administration three times a week,
(D) NDV/FMW plus CQ or rapamycin (same dose as in the above groups), CQ or rapamycin was administrated 1 d before virus injection. (A-D)
One week after treatment, tumor tissue samples from two different animals from each treatment group (of six) were subjected to either
hematoxylin–eosin (H&E) staining (The upper of A and B, tumor necrosis indicated by the arrows) or TUNEL assay (The lower of A and B,
arrowheads indicate brown 3,3'-diaminobenzidine chromogen in cell nuclei) or immunoblot analysis of cleaved caspase-3 levels and LC3II
abundance (C, D). β-Actin was used as a loading control. (E, F) Mice were treated as described above for two weeks. Tumor volumes were
measured at 5-day intervals for 40 days after injections and expressed as the mean ± SD (n = 10) in tumor volume–time curves. The difference in
tumor regression was significant between the virus-treated and vehicle groups (*p < 0.05; **p < 0.01); group receiving the combined treatment
and the single-treatment (virus alone or drugs alone) group (*p < 0.05; **p < 0.01). No statistically significant difference was observed between the
groups receiving the single treatments and vehicle-treated group.
Jiang et al. BMC Cancer 2014, 14:551 Page 13 of 15
http://www.biomedcentral.com/1471-2407/14/551prosurvival role in cisplatin-resistant SKOV3 ovarian can-
cer cells [52]. In line with these findings, we also detected
high basal levels of autophagy in A549/DDP cells, suggest-
ing that autophagy may act as a survival mechanism in
cisplatin-resistant A549 lung cancer cells. Therefore, it is
reasonable that, to induce oncolysis, oncolytic NDV/FMW
should inhibit the autophagic process in A549/DDP cells.
Surprisingly, the role of autophagy in paclitaxel-resistant
cancer cells remains controversial. Ajabnoor et al. reported
that an increased autophagic response was observed in
paclitaxel-resistant MCF-7 breast cancer cells with reduced
phosphor-mTOR and a relative resistance to the mTOR in-
hibitors rapamycin and RAD001 [53], suggesting that
autophagy may act as a survival mechanism in paclitaxel-
resistant breast cancer cells. However, Veldhoen et al. dem-
onstrated that paclitaxel inhibits autophagy in MCF-7 and
SK-BR-3 breast cancer cells [54]. Moreover, Veldhoen et al.
showed that primary breast tumors that express diminished
levels of autophagy-initiating genes were resistant to taxane
therapy [54], suggesting that autophagy may act as a cell
death mechanism in PTX-resistant breast cancer cells. In
this study, we did not observe an increased basal level of
autophagy in A549/PTX cells compared with parental
A549 cells, indicating that autophagy may not act as a sur-
vival mechanism in A549/PTX cells. Accordingly, NDV/
FMW infection resulted in the induction of autophagy in
A549/PTX cells, suggesting that autophagy may play a posi-
tive role for NDV/FMW to exert its oncolytic effect in these
cells. Interestingly, although NDV/FMW triggered autoph-
agy in A549 cells, combination treatment with either rapa-
mycin or CQ did not induce increased apoptosis, indicating
that autophagy may not be involved in NDV/FMW-in-
duced oncolysis in A549 cells.
Currently, pharmacological autophagy modulators such
as rapamycin and CQ and their analogs or derivatives have
been widely used in combination with OVs to enhance vir-
otherapy for a variety of cancers in preclinical trials
[26,40-42]. However, whether autophagy inducers or inhibi-
tors are used in combination virotherapy may be virus
strain- and cancer line-dependent. Here, we presented
in vitro evidence that rapamycin enhances NDV/FMW-mediated oncolysis in A549/PTX cells via increased au-
tophagy, while CQ augments the antitumor effects of
NDV/FMW on A549/DDP cells via inhibition of
autophagosome-lysosome fusion, which is in agreement
with the way in which NDV/FMW perturbs the cellular au-
tophagy machinery in these drug-resistant lung cancer cells.
The increase in NDV/FMW-mediated cytotoxicity in the
presence of autophagy modulators may be due to the aug-
mented activation of apoptosis and necrosis as demon-
strated by enhanced capase-3 activation and increased
numbers of apoptotic and necrotic cells. However, combin-
ation treatments may exert their effects via enhanced viral
propagation. Interestingly, CQ treatment significantly re-
duced the yield of NDV/FMW progeny in A549/DDP cells,
while pretreatment with rapamycin did not alter viral titers,
suggesting that the increase in viral cytotoxicity in the pres-
ence of the autophagy inhibitor CQ might be due to en-
hanced activation of apoptosis and necrosis rather than
altered viral replication. In contrast, pretreatment with ei-
ther rapamycin or CQ did not significantly alter virus yield
in NDV/FMW-infected A549/PTX cells, excluding a role
for viral propagation in enhanced viral cytotoxicity by com-
bination treatments. This notion is in agreement with stud-
ies of other OVs with combination therapies. Botta et al.
reported that the inhibition of autophagy by CQ enhances
the effects of the oncolytic adenovirus dl922-947 against
glioma cells, while viral replication is not increased by au-
tophagy modulation [26]. Our in vivo data further indicated
that NDV/FMW in combination with rapamycin or CQ in-
duces enhanced caspase-3 activation accompanied by in-
creased LC3II abundance in A549/PTX- and A549/DDP-
derived tumors. However, it should be noted that the con-
tribution of autophagic modulators rapamycin and CQ on
antitumor immunity and thus the efficacy of oncolytic vir-
otherapy have not been taken into consideration in our
in vivo experiments. OVs can induce autophagy and im-
munogenic cancer cell death which may be potentiated by
co-administration with autophagy modulators as modula-
tion of autophagy may enhance tumor immunogenecity
[29]. It was reported that the combination of oncolytic
adenovirus with low-dose temozolomide increased tumor
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chemotherapy-refractory cancer patients [30]. Therefore,
further in vivo studies are required to clarify the roles of
rapamycin and CQ in antitumor immunity contributing to
the overall efficacy of NDV-mediated virotherapy.
Conclusions
In the current study, we provide evidence that pharma-
cological autophagy modulation enhanced the in vitro
and in vivo oncolytic effects of NDV/FMW in drug-
resistant lung cancer cells. Our findings suggest that the
combination of NDV/FMW and autophagy modulators
may be a novel treatment option for lung cancer patients
with recurrent disease after cisplatin- or paclitaxel-based
first-line chemotherapy. Of note, recent study demon-
strated that drug-resistant NSCLC cell lines may display
a stem-like signature [55,56], linking cancer stem cell
with drug resistance. Therefore, it will be interesting to
extend our study to lung cancer stem cell.
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